Terms: = Ovarian cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Prognosis
24 results:
1. Tissue Expression and Prognostic Role of CXCL12 and cxcr4 in High-grade Serous ovarian Carcinoma.
Lim H; Kim SI; Kim EN; Lee M; Lee C; Kim JW; Chung HH
Anticancer Res; 2023 Jul; 43(7):3331-3340. PubMed ID: 37351997
[TBL] [Abstract] [Full Text] [Related]
2. cxcr4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma.
Zi D; Li Q; Xu CX; Zhou ZW; Song GB; Hu CB; Wen F; Yang HL; Nie L; Zhao X; Tan J; Zhou SF; He ZX
Aging (Albany NY); 2022 Jun; 14(11):4673-4698. PubMed ID: 35681259
[TBL] [Abstract] [Full Text] [Related]
3. Effect of bevacizumab combined with chemotherapy on SDF-1 and cxcr4 in epithelial ovarian cancer and its prognosis.
Ma C
World J Surg Oncol; 2022 May; 20(1):154. PubMed ID: 35545781
[TBL] [Abstract] [Full Text] [Related]
4. High ratio of pcxcr4/cxcr4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy.
Walther F; Berther JL; Lalos A; Ramser M; Eichelberger S; Mechera R; Soysal S; Muenst S; Posabella A; Güth U; Stadlmann S; Terracciano L; Droeser RA; Zeindler J; Singer G
BMC Cancer; 2022 Apr; 22(1):376. PubMed ID: 35397601
[TBL] [Abstract] [Full Text] [Related]
5. Determination of Potential Therapeutic Targets and Prognostic Markers of ovarian cancer by Bioinformatics Analysis.
Zhang J; Huang S; Quan L; Meng Q; Wang H; Wang J; Chen J
Biomed Res Int; 2021; 2021():8883800. PubMed ID: 33829065
[TBL] [Abstract] [Full Text] [Related]
6. Construction autophagy-related prognostic risk signature to facilitate survival prediction, individual treatment and biomarker excavation of epithelial ovarian cancer patients.
Fei H; Chen S; Xu C
J Ovarian Res; 2021 Mar; 14(1):41. PubMed ID: 33676525
[TBL] [Abstract] [Full Text] [Related]
7. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract] [Full Text] [Related]
8. Integrative analysis of the common genetic characteristics in ovarian cancer stem cells sorted by multiple approaches.
Zhang X; Su Y; Wu X; Xiao R; Wu Y; Yang B; Wang Z; Guo L; Kang X; Wang C
J Ovarian Res; 2020 Sep; 13(1):116. PubMed ID: 32977853
[TBL] [Abstract] [Full Text] [Related]
9. Circulating Tumor Cells Characterization Revealed TIMP1 as a Potential Therapeutic Target in ovarian cancer.
Abreu M; Cabezas-Sainz P; Alonso-Alconada L; Ferreirós A; Mondelo-Macía P; Lago-Lestón RM; Abalo A; Díaz E; Palacios-Zambrano S; Rojo-Sebastian A; López-López R; Sánchez L; Moreno-Bueno G; Muinelo-Romay L
Cells; 2020 May; 9(5):. PubMed ID: 32423054
[TBL] [Abstract] [Full Text] [Related]
10. Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer.
Gong G; Lin T; Yuan Y
J Ovarian Res; 2020 Mar; 13(1):30. PubMed ID: 32192517
[TBL] [Abstract] [Full Text] [Related]
11. The prognostic value of cxcr4 in ovarian cancer: a meta-analysis.
Liu CF; Liu SY; Min XY; Ji YY; Wang N; Liu D; Ma N; Li ZF; Li K
PLoS One; 2014; 9(3):e92629. PubMed ID: 24658065
[TBL] [Abstract] [Full Text] [Related]
12. Imaging CXCL12-cxcr4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract] [Full Text] [Related]
13. The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer.
Popple A; Durrant LG; Spendlove I; Rolland P; Scott IV; Deen S; Ramage JM
Br J Cancer; 2012 Mar; 106(7):1306-13. PubMed ID: 22415233
[TBL] [Abstract] [Full Text] [Related]
14. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-cxcr4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract] [Full Text] [Related]
15. Expression of cxcr4 indicates poor prognosis in patients with clear cell carcinoma of the ovary.
Sekiya R; Kajiyama H; Sakai K; Umezu T; Mizuno M; Shibata K; Yamamoto E; Fujiwara S; Nagasaka T; Kikkawa F
Hum Pathol; 2012 Jun; 43(6):904-10. PubMed ID: 22169254
[TBL] [Abstract] [Full Text] [Related]
16. Chemokine axes CXCL12/cxcr4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma.
Guo L; Cui ZM; Zhang J; Huang Y
Chin J Cancer; 2011 May; 30(5):336-43. PubMed ID: 21527066
[TBL] [Abstract] [Full Text] [Related]
17. Positron emission tomography imaging of tumors expressing the human chemokine receptor cxcr4 in mice with the use of 64Cu-AMD3100.
Weiss ID; Jacobson O; Kiesewetter DO; Jacobus JP; Szajek LP; Chen X; Farber JM
Mol Imaging Biol; 2012 Feb; 14(1):106-14. PubMed ID: 21347799
[TBL] [Abstract] [Full Text] [Related]
18. PET of tumor cxcr4 expression with 4-18F-T140.
Jacobson O; Weiss ID; Kiesewetter DO; Farber JM; Chen X
J Nucl Med; 2010 Nov; 51(11):1796-804. PubMed ID: 20956475
[TBL] [Abstract] [Full Text] [Related]
19. High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ; Zhu S; Bruggeman R; Zaino RJ; Evans DB; Fleming JB; Gomez HF; Zander DS; Wang H
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2598-604. PubMed ID: 20732965
[TBL] [Abstract] [Full Text] [Related]
20. Role of CXCL12 in metastasis of human ovarian cancer.
Jiang YP; Wu XH; Xing HY; DU XY
Chin Med J (Engl); 2007 Jul; 120(14):1251-5. PubMed ID: 17697577
[TBL] [Abstract] [Full Text] [Related]
[Next]
